

DOCKET NO: ISIS0064-100 (RTS-0175)

PATENT

IN THE CLAIMS:

Please amend claim 1 as follows.

Claim 1 (currently amended) A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding human dual specific phosphatase 5 (SEQ ID NO:10), wherein said compound ~~specifically hybridizes with~~ and inhibits the expression of human dual specific phosphatase 5 by at least 40%.

Claim 2 (original) The compound of claim 1 which is an antisense oligonucleotide.

Claim 3 (canceled)

Claim 4 (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 5 (original) The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 6 (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 7 (original) The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

Claim 8 (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9 (original) The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

DOCKET NO: ISIS0064-100 (RTS-0175)

PATENT

Claim 10 (original) The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 11 (canceled)

Claim 12 (original) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13 (original) The composition of claim 12 further comprising a colloidal dispersion system.

Claim 14 (original) The composition of claim 12 wherein the compound is an antisense oligonucleotide.

Claim 15 (previously presented) A method of inhibiting the expression of dual specific phosphatase 5 in cells or tissues comprising contacting said cells or tissues *in vitro* with the compound of claim 1 so that expression of dual specific phosphatase 5 is inhibited.

Claims 16-20 (canceled)